SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

PURPOSE: Androgen deprivation therapy (ADT), an important treatment for advanced prostate cancer, is highly variable in its effectiveness. We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT. PATIENTS AND METHODS: A cohor...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Yang, Ming, Xie, Wanling, Mostaghel, Elahe, Nakabayashi, Mari, Werner, Lillian, Sun, Tong, Pomerantz, Mark, Freedman, Matthew, Ross, Robert, Regan, Meredith, Sharifi, Nima, Figg, William Douglas, Balk, Steven, Brown, Myles, Taplin, Mary-Ellen, Oh, William K., Lee, Gwo-Shu Mary, Kantoff, Philip W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2011
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3138634/
https://ncbi.nlm.nih.gov/pubmed/21606417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.2405
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller